{"id":303,"date":"2026-02-18T16:12:56","date_gmt":"2026-02-18T14:12:56","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=303"},"modified":"2026-09-10T10:51:59","modified_gmt":"2026-09-10T07:51:59","slug":"semaglutide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/","title":{"rendered":"Semaglutid 10 mg"},"content":{"rendered":"<p><strong>Semaglutid <\/strong><strong>10 mg in Europe | <\/strong><em>Chcete si v Evrop\u011b koupit semaglutid? Spole\u010dnost Life Peptide dod\u00e1v\u00e1 semaglutid vysok\u00e9 \u010distoty pro laboratorn\u00ed v\u00fdzkum a zaji\u0161\u0165uje spolehlivou dopravu po cel\u00e9 EU.<\/em><\/p>\n<h4><strong>Available in two formats<\/strong><\/h4>\n<p><em>Choose between a conventional lyophilized vial and a dual-chamber cartridge.<\/em><\/p>\n<p>The cartridge keeps Semaglutide and its diluent in separate chambers until activation. This avoids transporting the peptide as a premixed solution and simplifies laboratory preparation by removing the separate liquid-transfer step. Final dual-chamber cartridge concentration: 10 mg in 1 mL. A compatible reusable device is required.<\/p>\n<hr \/>\n<p>Semaglutid je <strong>dlouhodob\u011b p\u016fsob\u00edc\u00ed agonista receptoru GLP-1<\/strong> navr\u017een tak, aby napodoboval aktivitu endogenn\u00edho glukagon-like peptidu-1 a z\u00e1rove\u0148 poskytoval podstatn\u011b del\u0161\u00ed biologickou aktivitu ne\u017e p\u0159irozen\u00fd hormon. Na rozd\u00edl od <a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\">Tirzepatid<\/a> a <a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\">Retatrutid<\/a>, Semaglutid aktivuje pouze receptor GLP-1, co\u017e z n\u011bj \u010din\u00ed nejjednodu\u0161\u0161\u00edho \u010dlena sou\u010dasn\u00e9 generace inkretinov\u00fdch peptid\u016f. Tento selektivn\u00ed mechanismus u\u010dinil ze semaglutidu <strong>jedna z nejrozs\u00e1hleji zkouman\u00fdch metabolick\u00fdch peptid\u016f<\/strong> v obou preklinick\u00fdch a klinick\u00fdch v\u00fdzkumech za posledn\u00ed dek\u00e1du.<\/p>\n<p>Kv\u016fli tomuto rozs\u00e1hl\u00e9mu souboru d\u016fkaz\u016f se semaglutid \u010dasto pou\u017e\u00edv\u00e1 jako <strong>referen\u010dn\u00ed slou\u010denina<\/strong> p\u0159i hodnocen\u00ed nov\u011bj\u0161\u00edch du\u00e1ln\u00edch a trojit\u00fdch agonist\u016f receptor\u016f.<\/p>\n<hr \/>\n<h4><strong>Pro\u010d semaglutid z\u016fst\u00e1v\u00e1 d\u016fle\u017eit\u00fd ve v\u00fdzkumu metabolismu<\/strong><\/h4>\n<p>A\u010dkoli nov\u011bj\u0161\u00ed multi-receptorov\u00ed agonist\u00e9 p\u0159it\u00e1hli zna\u010dnou pozornost, semaglutid nad\u00e1le slou\u017e\u00ed jako v\u011bdeck\u00fd benchmark pro biologii GLP-1.<\/p>\n<p>Publikovan\u00fd v\u00fdzkum zkoumal semaglutid ve vztahu k:<\/p>\n<ul>\n<li><strong>regulace chuti k j\u00eddlu<\/strong><\/li>\n<li><strong>sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti<\/strong><\/li>\n<li><strong>glykemick\u00e1 kontrola<\/strong><\/li>\n<li><strong>sekrece inzul\u00ednu<\/strong><\/li>\n<li><strong>vypr\u00e1zd\u0148ov\u00e1n\u00ed \u017ealudku<\/strong><\/li>\n<li><strong>kardiovaskul\u00e1rn\u00ed v\u00fdsledky<\/strong><\/li>\n<li><strong>metabolick\u00fd syndrom<\/strong><\/li>\n<li><strong>Nenalkoholov\u00e1 steat\u00f3za jater<\/strong><\/li>\n<li><strong>dlouhodob\u00e9 inkretinov\u00e9 signalizace<\/strong><\/li>\n<\/ul>\n<p>Rozs\u00e1hl\u00e1 klinick\u00e1 literatura ji \u010din\u00ed jedn\u00edm z nejd\u016fle\u017eit\u011bj\u0161\u00edch srovn\u00e1vac\u00edch molekul v obezitn\u00edm a metabolick\u00e9m v\u00fdzkumu. Mnoho modern\u00edch studi\u00ed hodnot\u00edc\u00edch Tirzepatid, Retatrutid a nov\u011b vznikaj\u00edc\u00ed kombinace GLP-1 pou\u017e\u00edv\u00e1 Semaglutid jako <strong>referen\u010dn\u00ed standard<\/strong>.<\/p>\n<h4><strong>Jak funguje semaglutid<\/strong><\/h4>\n<p>Semaglutid <strong>selektivn\u011b aktivuje receptor GLP-1<\/strong>, kl\u00ed\u010dov\u00fd regul\u00e1tor chuti k j\u00eddlu, homeost\u00e1zy gluk\u00f3zy a gastrointestin\u00e1ln\u00edho signalizov\u00e1n\u00ed.<\/p>\n<p>Aktivace receptor\u016f GLP-1 byla v publikovan\u00e9m v\u00fdzkumu spojena s:<\/p>\n<ul>\n<li>inzulinov\u00e1 sekrece z\u00e1visl\u00e1 na gluk\u00f3ze<\/li>\n<li>potla\u010den\u00ed uvol\u0148ov\u00e1n\u00ed glukagonu<\/li>\n<li>zpomalen\u00e9 vyprazd\u0148ov\u00e1n\u00ed zaludku<\/li>\n<li>sn\u00ed\u017een\u00fd p\u0159\u00edjem potravy<\/li>\n<li>zm\u011bn\u011bn\u00e1 centr\u00e1ln\u00ed signalizace chuti k j\u00eddlu<\/li>\n<li>zlep\u0161en\u00ed n\u011bkolika metabolick\u00fdch marker\u016f<\/li>\n<\/ul>\n<p>Na rozd\u00edl od Tirzepatidu Semaglutid <strong>ne<\/strong> aktivovat receptory GIP. Na rozd\u00edl od Retatrutidu m\u00e1 <strong>bez glukagonu<\/strong> aktivita receptoru.<\/p>\n<p>Jeho hodnota proto spo\u010d\u00edv\u00e1 v poskytnut\u00ed dob\u0159e charakterizovan\u00e9ho <strong>GLP-1 model s jednou cestou<\/strong>, co\u017e z n\u011bj \u010din\u00ed logick\u00fd srovn\u00e1vac\u00ed standard pro nov\u011bj\u0161\u00ed inkretinov\u00e9 slou\u010deniny.<\/p>\n<h4><strong>Publikovan\u00e9 klinick\u00e9 n\u00e1lezy o semaglutidu<\/strong><\/h4>\n<p>Semaglutid m\u00e1 jeden z <strong>nejv\u011bt\u0161\u00ed lidsk\u00fd d\u016fkaz<\/strong> z\u00e1klady jak\u00e9hokoli peptidu v sou\u010dasnosti pou\u017e\u00edvan\u00e9ho v metabolick\u00e9m v\u00fdzkumu.<\/p>\n<p>V klinick\u00e9m programu STEP, semaglutid pod\u00e1van\u00fd jednou t\u00fddn\u011b produkoval <strong>v\u00fdznamn\u00e9 sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti<\/strong> v pr\u016fb\u011bhu 68t\u00fddenn\u00edch l\u00e9\u010debn\u00fdch obdob\u00ed, \u010d\u00edm\u017e se agonist\u00e9 GLP-1 receptor\u016f etablovali jako hlavn\u00ed terapeutick\u00e1 strategie pro v\u00fdzkum obezity.<\/p>\n<p>Krom\u011b v\u00fdsledk\u016f souvisej\u00edc\u00edch s hmotnost\u00ed prok\u00e1zaly n\u011bkolik velk\u00fdch klinick\u00fdch program\u016f zlep\u0161en\u00ed v:<\/p>\n<ul>\n<li>HbA1c<\/li>\n<li>la\u010dn\u00fd cukr<\/li>\n<li>obvod pasu<\/li>\n<li>krevn\u00ed tlak<\/li>\n<li>vybran\u00e9 kardiovaskul\u00e1rn\u00ed v\u00fdsledky<\/li>\n<li>kardio-metabolick\u00e9 rizikov\u00e9 ukazatele<\/li>\n<\/ul>\n<p>Proto\u017ee tato zji\u0161t\u011bn\u00ed byla reprodukov\u00e1na v mnoha nez\u00e1visl\u00fdch studi\u00edch, semaglutid z\u016fst\u00e1v\u00e1 <strong>hlavn\u00ed ukazatel<\/strong> proti kter\u00fdm jsou hodnoceny nov\u011bj\u0161\u00ed du\u00e1ln\u00ed a trojit\u00e9 agonistick\u00e9 peptidy.<\/p>\n<h4><strong>Publikovan\u00e9 v\u00fdsledky t\u00fdkaj\u00edc\u00ed se bezpe\u010dnosti a sn\u00e1\u0161enlivosti<\/strong><\/h4>\n<p>Publikovan\u00e9 klinick\u00e9 studie d\u016fsledn\u011b identifikuj\u00ed gastrointestin\u00e1ln\u00ed p\u0159\u00edhody jako nej\u010dast\u011bj\u0161\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky spojen\u00e9 se semaglutidem. Mezi \u010dasto uv\u00e1d\u011bn\u00e9 p\u0159\u00edhody pat\u0159\u00ed: nevolnost, zvracen\u00ed, pr\u016fjem, z\u00e1cpa a b\u0159i\u0161n\u00ed nepohodl\u00ed.<\/p>\n<p>V r\u00e1mci v\u0161ech hlavn\u00edch klinick\u00fdch program\u016f byly tyto jevy obecn\u011b nejv\u00fdrazn\u011bj\u0161\u00ed b\u011bhem <strong>zvy\u0161ov\u00e1n\u00ed d\u00e1vky<\/strong> a typicky byly pops\u00e1ny jako <strong>m\u00edrn\u00fd a\u017e st\u0159edn\u00ed<\/strong> z hlediska z\u00e1va\u017enosti. Stejn\u011b jako u jin\u00fdch agonist\u016f receptoru GLP-1 bylo postupn\u00e9 zvy\u0161ov\u00e1n\u00ed d\u00e1vky d\u016fle\u017eitou sou\u010d\u00e1st\u00ed zve\u0159ejn\u011bn\u00fdch v\u00fdzkumn\u00fdch protokol\u016f, jejich\u017e c\u00edlem bylo zlep\u0161it sn\u00e1\u0161enlivost.<\/p>\n<p>Tato sekce shrnuje publikovan\u00e1 zji\u0161t\u011bn\u00ed z investiga\u010dn\u00edho a klinick\u00e9ho v\u00fdzkumu semaglutidu a nen\u00ed ur\u010dena jako n\u00e1vod k pou\u017eit\u00ed tohoto produktu.<\/p>\n<h4><strong>Publikovan\u00e9 d\u00e1vkovac\u00ed re\u017eimy pou\u017e\u00edvan\u00e9 ve v\u00fdzkumu Semaglutidu<\/strong><\/h4>\n<p>Publikovan\u00e9 studie semaglutidu obecn\u011b vyu\u017e\u00edvaly pod\u00e1v\u00e1n\u00ed jednou t\u00fddn\u011b s postupn\u00fdm zvy\u0161ov\u00e1n\u00edm d\u00e1vky, co\u017e umo\u017enilo zkoumaj\u00edc\u00edm hodnotit \u00fa\u010dinnost i gastrointestin\u00e1ln\u00ed sn\u00e1\u0161enlivost b\u011bhem prodlou\u017een\u00fdch l\u00e9\u010debn\u00fdch obdob\u00ed.<\/p>\n<p>V r\u00e1mci hlavn\u00edch program\u016f zam\u011b\u0159en\u00fdch na obezitu a cukrovku, <strong>protokoly pro eskalaci<\/strong> byly pou\u017eity p\u0159ed dosa\u017een\u00edm udr\u017eovac\u00edch d\u00e1vek, p\u0159i\u010dem\u017e studie pokra\u010dovaly a\u017e 68 t\u00fddn\u016f ve v\u00fdzkumu obezity. Publikovan\u00e1 literatura tedy odr\u00e1\u017e\u00ed strukturovan\u00fd design klinick\u00fdch studi\u00ed sp\u00ed\u0161e ne\u017e jeden univerz\u00e1ln\u00ed d\u00e1vkovac\u00ed re\u017eim.<\/p>\n<table style=\"height: 174px;\" width=\"698\">\n<thead>\n<tr>\n<td><strong>Kontext zve\u0159ejn\u011bn\u00e9 studie<\/strong><\/td>\n<td><strong>N\u00e1vrh studie<\/strong><\/td>\n<td><strong>Frekvence<\/strong><\/td>\n<td><strong>Doba trv\u00e1n\u00ed<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Program STEP pro obezitu<\/td>\n<td>postupn\u00e9 zvy\u0161ov\u00e1n\u00ed d\u00e1vky<\/td>\n<td>jednou t\u00fddn\u011b<\/td>\n<td>68 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td>Program SUSTAIN pro diabetes<\/td>\n<td>postupn\u00e9 zvy\u0161ov\u00e1n\u00ed d\u00e1vky<\/td>\n<td>jednou t\u00fddn\u011b<\/td>\n<td>rozmanit\u00fd<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Tyto harmonogramy shrnuj\u00ed publikovan\u00e9 n\u00e1vrhy klinick\u00fdch studi\u00ed a nejsou n\u00e1vodem k pou\u017eit\u00ed tohoto produktu.<\/p>\n<h4><strong>Semaglutid vs. tirzepatid vs. retatrutid<\/strong><\/h4>\n<p><strong>Semaglutid<\/strong><\/p>\n<ul>\n<li>Agonista receptoru GLP-1<\/li>\n<li><strong>svobodn\u00fd<\/strong> mechanismus receptoru<\/li>\n<li>nejv\u011bt\u0161\u00ed datab\u00e1ze klinick\u00fdch d\u016fkaz\u016f<\/li>\n<li>referen\u010dn\u00ed slou\u010denina pro v\u00fdzkum GLP-1<\/li>\n<\/ul>\n<p><strong>Tirzepatid<\/strong><\/p>\n<ul>\n<li>GLP-1 + GIP <strong>du\u00e1ln\u00ed<\/strong> agonista<\/li>\n<li>\u0161ir\u0161\u00ed inkretinov\u00e1 signalizace<\/li>\n<li>\u010dasto p\u0159\u00edmo srovn\u00e1van\u00fd se semaglutidem<\/li>\n<\/ul>\n<p><strong>Retatrutid<\/strong><\/p>\n<ul>\n<li>GLP-1 + GIP + glukagon <strong>trojn\u00e1sobn\u00fd<\/strong> agonista<\/li>\n<li>nej\u0161ir\u0161\u00ed spektrum receptor\u016f<\/li>\n<li>p\u0159edstavuje nejnov\u011bj\u0161\u00ed generaci multireceptorov\u00fdch metabolick\u00fdch peptid\u016f<\/li>\n<\/ul>\n<p>Pro v\u00fdzkumn\u00edky zkoumaj\u00edc\u00ed inkretinovou biologii poskytuje semaglutid z\u00e1klad, ze kter\u00e9ho lze vyhodnocovat slou\u010deniny s du\u00e1ln\u00edmi a trojit\u00fdmi agonisty.<\/p>\n<h4><strong>Vlastnosti produktu<\/strong><\/h4>\n<p>Aplikace: laboratorn\u00ed a analytick\u00fd v\u00fdzkum<br \/>\nPou\u017eit\u00ed omezen\u00e9: nen\u00ed ur\u010deno k lidsk\u00e9 spot\u0159eb\u011b; pro l\u00e9ka\u0159sk\u00e9, veterin\u00e1rn\u00ed ani kosmetick\u00e9 pou\u017eit\u00ed<br \/>\nVyrobeno v za\u0159\u00edzen\u00edch spl\u0148uj\u00edc\u00edch spr\u00e1vnou v\u00fdrobn\u00ed praxi (GMP) za p\u0159\u00edsn\u00fdch protokol\u016f kontroly kvality.<br \/>\nKa\u017ed\u00e1 \u0161ar\u017ee je po v\u00fdrob\u011b pe\u010dliv\u011b laboratorn\u011b testov\u00e1na (Certifik\u00e1t o anal\u00fdze najdete pod obr\u00e1zky produkt\u016f).<br \/>\nLyofilizov\u00e1no (su\u0161eno mrazem) pro maxim\u00e1ln\u00ed stabilitu a prodlou\u017eenou trvanlivost.<br \/>\nUzav\u0159eno ve steriln\u00edch lahvi\u010dk\u00e1ch, p\u0159ipraveno k rekonstituci.<br \/>\n\u010cistota: \u226599% (testov\u00e1no metodou HPLC)<br \/>\nVzhled: Lyofilizovan\u00fd b\u00edl\u00fd\/neb\u00edle b\u00edl\u00fd pr\u00e1\u0161ek<br \/>\nMolekul\u00e1rn\u00ed vzorec: C<sub>187<\/sub>H<sub>291<\/sub>N<sub>45<\/sub>O<sub>59<\/sub><br \/>\nMolekulov\u00e1 hmotnost: 4113,64<br \/>\nHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-\u03b3-Glu-17-karboxyheptadekanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly<br \/>\n<strong>\u00dalo\u017ei\u0161t\u011b<\/strong>Neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky jsou nejl\u00e9pe skladov\u00e1ny <strong>chlazen\u00e9 p\u0159i 2\u20138 \u00b0C<\/strong>, co\u017e je metoda skladov\u00e1n\u00ed potvrzen\u00e1 na\u0161\u00edm v\u00fdrobn\u00edm partnerem a vhodn\u00e1 a\u017e po dobu 24 m\u011bs\u00edc\u016f. Preferuje se chlazen\u00ed, proto\u017ee minimalizuje zbyte\u010dn\u00e9 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed b\u011bhem b\u011b\u017en\u00e9 manipulace. Pokud je vy\u017eadov\u00e1no podstatn\u011b del\u0161\u00ed skladov\u00e1n\u00ed, lze zmrazen\u00e9 uchov\u00e1vat i neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky. Po rekonstituci v\u017edy skladujte p\u0159i 2\u20138 \u00b0C a nezmrazujte.<\/p>\n<h4><strong>Rekonstituce a manipulace<\/strong><\/h4>\n<p>Semaglutide je dod\u00e1v\u00e1n jako lyofilizovan\u00e1 lahvi\u010dka a m\u011blo by s n\u00edm b\u00fdt zach\u00e1zeno za pou\u017eit\u00ed standardn\u00edch postup\u016f rekonstituce peptid\u016f vhodn\u00fdch pro v\u00fdzkumn\u00e9 prost\u0159ed\u00ed. Mus\u00ed b\u00fdt rekonstituov\u00e1n pomoc\u00ed <a href=\"https:\/\/life-peptide.com\/cs\/product\/bac-10-ml\/\">bakteriostatick\u00e1 voda<\/a> p\u0159ed pou\u017eit\u00edm. Peptidy t\u0159\u00eddy GLP-1 se n\u011bkdy rozpou\u0161t\u011bj\u00ed pomalu a vy\u017eaduj\u00ed velmi jemn\u00e9 rozpou\u0161t\u011bn\u00ed, aby se zabr\u00e1nilo p\u011bn\u011bn\u00ed nebo vzniku m\u00edrn\u00e9ho z\u00e1kalu.<\/p>\n<p>Pro dal\u0161\u00ed pokyny k v\u00fdb\u011bru rozpou\u0161t\u011bdla, pl\u00e1nov\u00e1n\u00ed koncentrac\u00ed a skladov\u00e1n\u00ed viz \u00fapln\u00e9 <a href=\"https:\/\/life-peptide.com\/cs\/reconstitution-of-peptides\/\">Pr\u016fvodce rekonstituc\u00ed peptid\u016f<\/a> a <a href=\"https:\/\/life-peptide.com\/cs\/calculator\/\">Kalkula\u010dka rekonstituce<\/a>.<\/p>\n<h4>Kl\u00ed\u010dov\u00e9 publikovan\u00e9 studie<\/h4>\n<ul>\n<li>Wilding JPH a kol. \u201c<em>T\u00fddenn\u00ed pod\u00e1v\u00e1n\u00ed semaglutidu dosp\u011bl\u00fdm s nadv\u00e1hou nebo obezitou. New England Journal of Medicine<\/em>, 2021.<\/li>\n<li>Frias JP, Davies MJ, Rosenstock J, et al.\u00a0<em>Porovn\u00e1n\u00ed tirzepatidu a semaglutidu pod\u00e1van\u00fdch jednou t\u00fddn\u011b u pacient\u016f s diabetes mellitus 2. typu (SURPASS-2). New England Journal of Medicine<\/em>. 2021.<\/li>\n<li>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.\u00a0<em>Semaglutid a kardiovaskul\u00e1rn\u00ed d\u016fsledky u obezity bez diabetu (SELECT). New England Journal of Medicine<\/em>. 2023.<\/li>\n<li>Aroda VR.\u00a0<em>P\u0159ehled klinick\u00e9ho programu SUSTAIN. Diabetes, Obesity and Metabolism<\/em>. 2019.<\/li>\n<\/ul>\n<hr \/>\n<h4><strong>\u010casto kladen\u00e9 ot\u00e1zky<\/strong><\/h4>\n<p><strong>Co je semaglutid?<\/strong><\/p>\n<p>Semaglutid je dlouhodob\u011b p\u016fsob\u00edc\u00ed agonista receptoru GLP-1, kter\u00fd napodobuje p\u016fsoben\u00ed p\u0159irozen\u011b se vyskytuj\u00edc\u00edho inkretinov\u00e9ho hormonu glukagonu podobn\u00e9ho peptidu-1. Stal se jedn\u00edm z nejrozs\u00e1hleji studovan\u00fdch metabolick\u00fdch peptid\u016f a slou\u017e\u00ed jako referen\u010dn\u00ed slou\u010denina pro modern\u00ed v\u00fdzkum GLP-1. Zve\u0159ejn\u011bn\u00e9 studie zkoumaly semaglutid z hlediska regulace chuti k j\u00eddlu, gluk\u00f3zov\u00e9 homeost\u00e1zy, vlivu na t\u011blesnou hmotnost a \u0161ir\u0161\u00edch kardiometabolick\u00fdch sign\u00e1ln\u00edch drah.<\/p>\n<p><strong>Jak funguje semaglutid?<\/strong><\/p>\n<p>Semaglutid selektivn\u011b aktivuje GLP-1 receptor, dr\u00e1hu pod\u00edlej\u00edc\u00ed se na regulaci sekrece inzul\u00ednu, uvol\u0148ov\u00e1n\u00ed glukagonu, vyprazd\u0148ov\u00e1n\u00ed \u017ealudku a signalizaci chuti k j\u00eddlu. Na rozd\u00edl od nov\u011bj\u0161\u00edch du\u00e1ln\u00edch a triplov\u00fdch receptorov\u00fdch agonist\u016f p\u016fsob\u00ed pouze na GLP-1 receptory, co\u017e z n\u011bj \u010din\u00ed d\u016fle\u017eitou referen\u010dn\u00ed molekulu pro v\u00fdzkumn\u00edky porovn\u00e1vaj\u00edc\u00ed r\u016fzn\u00e9 terapeutick\u00e9 strategie zalo\u017een\u00e9 na inkretinech.<\/p>\n<p><strong>Jak se semaglutid li\u0161\u00ed od tirzepatidu?<\/strong><\/p>\n<p>Semaglutid aktivuje pouze GLP-1 receptor, zat\u00edmco tirzepatid je du\u00e1ln\u00ed agonista GLP-1\/GIP. Ob\u011b slou\u010deniny pat\u0159\u00ed do t\u0159\u00eddy inkretin\u016f, ale tirzepatid roz\u0161i\u0159uje mechanismus nad r\u00e1mec signalizace GLP-1. V d\u016fsledku toho se semaglutid \u010dasto pou\u017e\u00edv\u00e1 jako referen\u010dn\u00ed bod (benchmark), proti kter\u00e9mu se du\u00e1ln\u00ed agonisti v metabolick\u00e9m v\u00fdzkumu hodnot\u00ed.<\/p>\n<p><strong>Jak se Semaglutid li\u0161\u00ed od Retatrutidu?<\/strong><\/p>\n<p>Retatrutid je trojit\u00fd agonista, kter\u00fd c\u00edl\u00ed na receptory GLP-1, GIP a glukagonu, co\u017e mu d\u00e1v\u00e1 nej\u0161ir\u0161\u00ed profil receptor\u016f, jak\u00fd je v sou\u010dasnosti mezi inkretinov\u00fdmi peptidy zkoum\u00e1n. Semaglutid se naproti tomu zam\u011b\u0159uje v\u00fdhradn\u011b na aktivaci receptoru GLP-1. D\u00edky tomu je Semaglutid z\u00e1kladn\u00ed referen\u010dn\u00ed molekulou pro biologii GLP-1, zat\u00edmco Retatrutid p\u0159edstavuje novou generaci v\u00fdzkumu v\u00edcereceptorov\u00e9ho metabolismu.<\/p>\n<p><strong>Pro\u010d je semaglutid st\u00e1le d\u016fle\u017eit\u00fd, kdy\u017e existuj\u00ed nov\u011bj\u0161\u00ed peptidy?<\/strong><\/p>\n<p>A\u010dkoli nov\u011bj\u0161\u00ed peptidy s dvojitou a trojitou agonistickou aktivitou vzbudily zna\u010dn\u00fd z\u00e1jem, semaglutid z\u016fst\u00e1v\u00e1 jednou z nejd\u016fle\u017eit\u011bj\u0161\u00edch l\u00e1tek v metabolick\u00e9m v\u00fdzkumu, proto\u017ee disponuje nejrozs\u00e1hlej\u0161\u00ed a nejzralej\u0161\u00ed sb\u00edrkou publikovan\u00fdch klinick\u00fdch d\u016fkaz\u016f. Mnoho studi\u00ed hodnot\u00edc\u00edch tirzepatid, retatrutid a dal\u0161\u00ed experiment\u00e1ln\u00ed peptidy i nad\u00e1le pou\u017e\u00edv\u00e1 semaglutid jako prim\u00e1rn\u00ed srovn\u00e1vac\u00ed l\u00e1tku, co\u017e z n\u011bj \u010din\u00ed kl\u00ed\u010dov\u00fd prvek pro pochopen\u00ed toho, jak se nov\u011bj\u0161\u00ed inkretinov\u00e9 terapie li\u0161\u00ed od zaveden\u00e9 agonistick\u00e9 terapie GLP-1 receptor\u016f.<\/p>\n<p><strong>V jak\u00fdch oblastech v\u00fdzkumu se semaglutid nej\u010dast\u011bji zkoum\u00e1?<\/strong><\/p>\n<p>Publikovan\u00e9 studie zkoumali semaglutid v \u0161irok\u00e9m spektru oblast\u00ed metabolick\u00e9ho v\u00fdzkumu, v\u010detn\u011b obezity, regulace t\u011blesn\u00e9 hmotnosti, signalizace chuti k j\u00eddlu, metabolismu gluk\u00f3zy, diabetu 2. typu, kardiovaskul\u00e1rn\u00edch v\u00fdsledk\u016f, jatern\u00edho onemocn\u011bn\u00ed z utu\u017een\u00ed tukem a dlouhodob\u00e9 biologie inkretin\u016f. D\u00edky sv\u00e9 rozs\u00e1hl\u00e9 d\u016fkazn\u00ed z\u00e1kladn\u011b je jedn\u00edm z nej\u010dast\u011bji citovan\u00fdch peptid\u016f v modern\u00edm metabolick\u00e9m v\u00fdzkumu.<\/p>\n<p><strong>V jak\u00e9 form\u011b se semaglutid dod\u00e1v\u00e1?<\/strong><\/p>\n<p>Tento produkt je dod\u00e1v\u00e1n jako 10 mg lyofilizovan\u00e9ho semaglutidu ve steriln\u00ed v\u00fdzkumn\u00e9 lahvi\u010dce. Ke ka\u017ed\u00e9 \u0161ar\u017ei je p\u0159ilo\u017een certifik\u00e1t anal\u00fdzy (COA) a u vybran\u00fdch \u0161ar\u017e\u00ed je k dispozici nez\u00e1visl\u00e9 analytick\u00e9 ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou. Produkt je ur\u010den v\u00fdhradn\u011b pro laboratorn\u00ed a analytick\u00fd v\u00fdzkum.<\/p>\n<p><strong>M\u016f\u017eu si v Evrop\u011b koupit Semaglutid?<\/strong><\/p>\n<p>Ano. Semaglutid zas\u00edl\u00e1me do v\u011bt\u0161iny evropsk\u00fdch zem\u00ed pomoc\u00ed spolehliv\u00fdch kur\u00fdrn\u00edch slu\u017eeb. Dostupn\u00e9 zp\u016fsoby dopravy a dodac\u00ed lh\u016fty se zobraz\u00ed b\u011bhem pokladny na z\u00e1klad\u011b va\u0161\u00ed c\u00edlov\u00e9 destinace.<\/p>\n<p><strong>Je tento produkt ur\u010den k lidsk\u00e9mu pou\u017eit\u00ed?<\/strong><\/p>\n<p>Ne. Semaglutid dod\u00e1van\u00fd spole\u010dnost\u00ed Life Peptide je ur\u010den v\u00fdhradn\u011b pro v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed ur\u010den k lidsk\u00e9 spot\u0159eb\u011b, diagnostice, l\u00e9\u010db\u011b ani prevenci nemoc\u00ed. Jak\u00e9koli zm\u00ednky o publikovan\u00fdch klinick\u00fdch studi\u00edch na t\u00e9to str\u00e1nce slou\u017e\u00ed v\u00fdhradn\u011b k shrnut\u00ed aktu\u00e1ln\u00ed v\u011bdeck\u00e9 literatury t\u00fdkaj\u00edc\u00ed se molekuly semaglutidu.<\/p>\n<h4><strong>Souvisej\u00edc\u00ed v\u00fdzkumn\u00fd kontext<\/strong><\/h4>\n<p>Semaglutid pat\u0159\u00ed do t\u0159\u00eddy agonist\u016f GLP-1 receptor\u016f v r\u00e1mci metabolick\u00e9ho v\u00fdzkumu zalo\u017een\u00e9ho na inkretinech. Pro mechanistick\u00e9 porovn\u00e1n\u00ed s du\u00e1ln\u00edmi a triagonsity viz na\u0161e <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Pr\u016fvodce v\u00fdzkumem metabolismu GLP-1<\/a>.<\/strong><\/p>\n<p>Proch\u00e1zet v\u0161echny slou\u010deniny v <a title=\"Kategorie metabolick\u00e9ho v\u00fdzkumu.\" href=\"\/cs\/product-category\/metabolic-research\/\"><strong>Kategorie metabolick\u00e9ho v\u00fdzkumu.<\/strong><\/a><\/p>\n<p>Pro porovn\u00e1n\u00ed drah:<\/p>\n<ul data-start=\"2633\" data-end=\"2702\">\n<li data-start=\"2633\" data-end=\"2671\">\n<p data-start=\"2635\" data-end=\"2671\">Du\u00e1ln\u00ed agonist\u00e9: \u00a0<a href=\"http:\/\/example.test\/product\/tirzepatide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Tirzepatid (GLP-1\/GIP)<\/a><\/p>\n<\/li>\n<li data-start=\"2672\" data-end=\"2702\">\n<p data-start=\"2674\" data-end=\"2702\">Trojit\u00ed agonist\u00e9: <a href=\"http:\/\/example.test\/product\/retatrutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Retatrutid (GLP-1\/GIP\/glukagon)<\/a><\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>POZN\u00c1MKA: <\/strong>Tento text slou\u017e\u00ed pouze pro vzd\u011bl\u00e1vac\u00ed \u00fa\u010dely a nep\u0159edstavuje l\u00e9ka\u0159skou pomoc.<\/p>\n<p><strong>Upozorn\u011bn\u00ed:<\/strong><br \/>\nTento produkt je prod\u00e1v\u00e1n pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed ur\u010den k diagnostice, l\u00e9\u010db\u011b, vyl\u00e9\u010den\u00ed nebo prevenci jak\u00fdchkoli onemocn\u011bn\u00ed. Kupuj\u00edc\u00ed p\u0159eb\u00edr\u00e1 plnou odpov\u011bdnost za \u0159\u00e1dnou manipulaci a pou\u017eit\u00ed.<\/p>","protected":false},"excerpt":{"rendered":"<p>Semaglutid 10 mg je GLP-1 receptorov\u00fd agonista pro v\u00fdzkumn\u00e9 \u00fa\u010dely dod\u00e1van\u00fd v lyofilizovan\u00e9 form\u011b pro laboratorn\u00ed pou\u017eit\u00ed. Jako jeden z nejrozs\u00e1hleji studovan\u00fdch inkretinov\u00fdch peptid\u016f se stal referen\u010dn\u00ed l\u00e1tkou pro v\u00fdzkum regulace chuti k j\u00eddlu, zm\u011bn t\u011blesn\u00e9 hmotnosti, metabolismu gluk\u00f3zy a kardiometabolick\u00e9 signalizace.<\/p>\n<p>||<\/p>\n<p>\u010cistota \u226599% | N\u00e1kup v Evrop\u011b s dopravou od 5 \u20ac | Mo\u017enost volby dopravy zdarma | P\u0159ij\u00edm\u00e1me platby kartou<\/p>","protected":false},"featured_media":1236,"template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,254,287,248,253,139,255,247,258,246],"class_list":["post-303","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-blood-glucose-research","product_tag-buy-semaglutide","product_tag-energy-balance","product_tag-glp-1-agonist","product_tag-glp-1-research","product_tag-incretin-signaling","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product\/303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media\/1236"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media?parent=303"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_brand?post=303"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_cat?post=303"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_tag?post=303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}